XML 56 R42.htm IDEA: XBRL DOCUMENT
v3.20.2

Collaboration and License Agreements - Additional Information (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
May 12, 2020 shares | Apr. 29, 2020 USD ($) $ / shares shares | Apr. 01, 2020 USD ($) HumanHostFactor | Mar. 10, 2020 USD ($) | Jun. 30, 2020 USD ($) | Apr. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) | Aug. 31, 2019 USD ($) | Sep. 30, 2018 USD ($) | Jul. 31, 2018 USD ($) | May 31, 2018 USD ($) | Oct. 31, 2017 USD ($) shares | Sep. 30, 2020 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock, value |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 323,214,000 |  |  |  | $ 323,214,000 |  |
License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,747,000 |  |
Stock Purchase Agreement | GGL |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock, shares | shares |  | 6,626,027 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share purchase price per share | $ / shares |  | $ 37.73 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock, value |  | $ 250,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of years conduct certain research and development activities under mutually agreed development plans |  | 4 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum percentage of right to perform details in connection with antibody product |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Addition (reduction) of research and development expense |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,200,000 |  |  |  | (2,600,000) |  |
Preliminary Collaboration Agreement | GSK | Accrued Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payable |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,600,000 |  |  |  | $ 2,600,000 |  |
Preliminary Collaboration Agreement | Antibody Program | GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development costs |  | 72.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement | Vaccine Program | GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of development costs |  | 27.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement and Stock Purchase Agreement | GSK |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium paid on sale price of common stock |  | $ 43,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  | 43,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair market value of the common stock issued |  | $ 206,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock price per share | $ / shares |  | $ 36.70 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Premium paid on sale price of common stock |  | $ 43,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for not exercising an option |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |
Written notice period for exercise an option |  |  |  |  |  |  |  |  |  |  |  | 180 days |  |  |  |  |  |  |  |
Written notice period for uncured material breach |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |  |
Written notice period for failure to make payment |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio Parent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of ordinary share equal to outstanding share |  |  |  |  |  |  |  |  |  |  |  | 9.90% |  |  |  |  |  |  |  |
Option exercise fee ranging from mid-single-digit |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |
Sales milestone receivable |  |  |  |  | 175,000,000.0 |  |  |  |  |  |  |  |  |  | 175,000,000.0 |  |  |  |  |
Estimated fair value of investments |  |  |  |  |  |  |  |  |  |  |  | $ 6,600,000 |  |  |  |  |  |  |  |
Contract liability |  |  |  |  | 2,700,000 |  |  |  |  |  |  |  |  |  | 2,700,000 |  |  |  |  |
Option exercise fee received |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Determined transaction price |  |  |  |  | 22,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment obligation expiration period after first commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |
Contract liability |  |  |  |  |  |  |  |  |  |  |  | 6,600,000 |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option exercise fee ranging from mid-single-digit |  |  |  |  |  |  |  |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  |
Option exercise fee of ranging from low tens |  |  |  |  |  |  |  |  |  |  |  | 50,000,000.0 |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | China Territory | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sales milestone receivable |  |  |  |  |  |  |  |  |  |  |  | 175,000,000.0 |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | United States | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale milestone payments |  |  |  |  |  |  |  |  |  |  |  | 175,000,000.0 |  |  |  |  |  |  |  |
Brii Agreement | Brii Bio | Other Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Carrying value of investment |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,700,000 |  |  |  | $ 5,700,000 |  | $ 6,600,000
Brii Agreement | Alnylam Pharmaceuticals Inc | Research and Development Expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from options exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000,000.0 |  |  |  |  |
Brii Agreement | Licensed Product-By-Licensed Product | Brii Bio Parent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment on basis ranging from mid-single-digit |  |  |  |  | 30,000,000.0 |  |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |  |  |
Brii Agreement | Licensed Product-By-Licensed Product | Brii Bio | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment on basis ranging from mid-single-digit |  |  |  |  |  |  |  |  |  |  |  | 30,000,000.0 |  |  |  |  |  |  |  |
Milestone payment on basis of ranging from low tens |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000.0 |  |  |  |  |  |  |  |
Brii Agreement | License | Brii Bio Parent |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 22,700,000 |  |  |  |  |
Alnylam Agreement | Alnylam Pharmaceuticals Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common stock, shares | shares | 1,111,111 |  |  |  |  |  |  |  |  |  |  |  | 1,111,111 |  |  |  |  |  |  |
Royalty payment obligation expiration period after first commercial sales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years |  |
Written notice period for exercise an option |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |
Written notice period for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |  |  |  |  |  |
Written notice period for failure to make payment |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |
Upfront fee paid |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |
Recognized liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 800,000
Maximum shares to be issued | shares |  |  |  |  |  |  |  |  |  |  |  |  | 1,111,111 |  |  |  |  |  |  |
Written notice period for licensed program other party challenges validity or enforceability of patent license. |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |  |
Embedded Derivative liability |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  | $ 0 |  | $ 0 | 13,600,000
Estimated fair value of the derivative liability |  |  |  | $ 29,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,400,000
Obligation payment |  |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  | $ 15,000,000.0 |  |  |  |
Milestone shares period issued |  |  |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development |  |  |  |  |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum number of human host factor targets related to susceptibility to corona viruses | HumanHostFactor |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment payable for achievement of specified development |  |  | $ 15,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments paid. |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 | $ 15,000,000.0 |  |  |  |
Expenses incurred under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  | 800,000 |  |  | 7,500,000 | $ 5,600,000 | 10,700,000 |
Alnylam Agreement | First siRNA product | Alnylam Pharmaceuticals Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  | $ 190,000,000.0 |  |  |  |  |  |  |
Alnylam Agreement | Each Infectious Disease siRNA | Alnylam Pharmaceuticals Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  | 115,000,000.0 |  |  |  |  |  |  |
Alnylam Agreement | Commercialization | Alnylam Pharmaceuticals Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  | 100,000,000.0 |  |  |  |  |  |  |
Maximum aggregate milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  |  |  | $ 250,000,000.0 |  |  |  |  |  |  |
Development and Manufacturing Collaboration Agreement | WuXi Biologics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Termination description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days’ prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days. |  |
Rockefeller Agreement | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee paid |  |  |  |  |  |  |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  | 40,000,000.0 |  |  |  |  |  |  |  |  |
Royalty Obligation Period From Date Of First Commercial Sale |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 years |  |
Rockefeller Agreement | Commercialization | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of annual license maintenance fees |  |  |  |  |  |  |  |  |  |  | 1,000,000.0 |  |  |  |  |  |  |  |  |
Rockefeller Agreement | First Infectious Disease Product | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  | 8,500,000 |  |  |  |  |  |  |  |  |
Rockefeller Agreement | First Four Other Infectious Disease Products | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  | 7,000,000.0 |  |  |  |  |  |  |  |  |
Rockefeller Agreement | Any Other Infectious Disease Product | Rockefeller |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum milestone payment for achievement of specified development and regulatory |  |  |  |  |  |  |  |  |  |  | $ 3,600,000 |  |  |  |  |  |  |  |  |
Rockefeller Agreement | HBV Program | Rockefeller | Research and Development Expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specified development milestones and annual license maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |
License maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  | $ 0 |  | $ 1,000,000.0 |
2018 MedImmune Agreement | MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement upfront payment |  |  |  |  |  |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |
2018 MedImmune Agreement | Influenza A and Influenza B | MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development, regulatory, and commercial milestone payments maximum amount |  |  |  |  |  |  |  |  |  | $ 331,500,000 |  |  |  |  |  |  |  |  |  |
2018 MedImmune Agreement | Influenza A | MedImmune |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Specified development milestones payment |  |  |  |  |  |  |  | 5,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |
2019 Xencor Agreement | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Written notice period for failure to make payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Written notice period for termination of licensed program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Written notice period for termination of licensed program based on challenge |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
2019 Xencor Agreement | Influenza A Research Programs | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  |  |  |  | $ 77,800,000 |  |  |  |  |  |  |  |  |  |  |
Specified development milestones payment |  |  |  |  |  |  |  | $ 800,000 |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate development and regulatory milestone payments |  |  |  |  |  |  |  |  | 17,800,000 |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate commercial sales milestone payments |  |  |  |  |  |  |  |  | 60,000,000.0 |  |  |  |  |  |  |  |  |  |  |
2019 Xencor Agreement | HBV Research Programs | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  |  |  |  | 77,800,000 |  |  |  |  |  |  |  |  |  |  |
Specified development milestones payment |  |  |  |  | $ 300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2019 Xencor Agreement | Influenza A and HBV Research Programs | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum aggregate milestone payments |  |  |  |  |  |  |  |  | $ 155,500,000 |  |  |  |  |  |  |  |  |  |  |
2020 Xencor Agreement | Xencor |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Written notice period for uncured material breach |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Written notice period for failure to make payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |
Licensed patents expiration period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 years |  |
Written notice period for termination of licensed program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 60 days |  |
Written notice period for termination of licensed program based on challenge |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of investments accounted under the cost method. + References No definition available. + Details
Name: | us-gaap_CostMethodInvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 860 -SubTopic 20 -Section 50 -Paragraph 4D -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (a),(c) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313 + Details
Name: | us-gaap_DerivativeFairValueOfDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959 + Details
Name: | us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sum of the carrying amounts as of the balance sheet date of all investments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.1(h)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_Investments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Costs and expenses for the period incurred under the collaboration agreements. + References No definition available. + Details
Name: | vir_CollaborationAgreementRelatedCostsAndExpenses
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration agreement termination description. + References No definition available. + Details
Name: | vir_CollaborationAgreementTerminationDescription
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Determined transaction price. + References No definition available. + Details
Name: | vir_DeterminedTransactionPrice
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Development, regulatory, and commercial milestone payments maximum amount. + References No definition available. + Details
Name: | vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair market value of common stock issued. + References No definition available. + Details
Name: | vir_FairMarketValueOfCommonStockIssued
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase (decrease) in research And development expense. + References No definition available. + Details
Name: | vir_IncreaseDecreaseInResearchAndDevelopmentExpense
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License agreement upfront payment. + References No definition available. + Details
Name: | vir_LicenseAgreementUpfrontPayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License maintenance fees. + References No definition available. + Details
Name: | vir_LicenseMaintenanceFees
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Licensed patents expiration period. + References No definition available. + Details
Name: | vir_LicensedPatentsExpirationPeriod
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum aggregate commercial sales milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateCommercialSalesMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate development and regulatory milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate milestone payment for achievement of specified development and regulatory. + References No definition available. + Details
Name: | vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum aggregate milestone payments. + References No definition available. + Details
Name: | vir_MaximumAggregateMilestonePayments
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum milestone payment for achievement of specified development. + References No definition available. + Details
Name: | vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum milestone payment for achievement of specified development and regulatory. + References No definition available. + Details
Name: | vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Maximum milestone payment payable for achievement of specified development. + References No definition available. + Details
Name: | vir_MaximumMilestonePaymentPayableForAchievementOfSpecifiedDevelopment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum number of human host factor targets related to susceptibility to corona viruses. + References No definition available. + Details
Name: | vir_MaximumNumberOfHumanHostFactorTargetsRelatedToSusceptibilityToCoronaViruses
Namespace Prefix: | vir_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum percentage of right to perform details in connection with antibody product. + References No definition available. + Details
Name: | vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
Namespace Prefix: | vir_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum shares to be issued. + References No definition available. + Details
Name: | vir_MaximumSharesToBeIssued
Namespace Prefix: | vir_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone payments paid. + References No definition available. + Details
Name: | vir_MilestonePaymentsPaid
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone shares period issued. + References No definition available. + Details
Name: | vir_MilestoneSharesPeriodIssued
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of years conduct certain research and development activities under mutually agreed development plans. + References No definition available. + Details
Name: | vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Option exercise fee consideration payable. + References No definition available. + Details
Name: | vir_OptionExerciseFeeConsiderationPayable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Option exercise fee consideration receivable. + References No definition available. + Details
Name: | vir_OptionExerciseFeeConsiderationReceivable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Option exercise fee received. + References No definition available. + Details
Name: | vir_OptionExerciseFeeReceived
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payable under agreement, current. + References No definition available. + Details
Name: | vir_PayableUnderAgreementCurrent
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment of annual license maintenance fees. + References No definition available. + Details
Name: | vir_PaymentOfAnnualLicenseMaintenanceFees
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of payment to a collaborator due to a program option exercise under a separate agreement . + References No definition available. + Details
Name: | vir_PaymentToPartnerResultingFromProgramOptionExercise
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of development costs. + References No definition available. + Details
Name: | vir_PercentageOfDevelopmentCosts
Namespace Prefix: | vir_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of ordinary share equal to outstanding share. + References No definition available. + Details
Name: | vir_PercentageOfOrdinaryShareEqualToOutstandingShare
Namespace Prefix: | vir_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Premium paid on sale price of common stock. + References No definition available. + Details
Name: | vir_PremiumPaidOnSalePriceOfCommonStock
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regulatory milestone consideration receivable. + References No definition available. + Details
Name: | vir_RegulatoryMilestoneConsiderationReceivable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Regulatory milestone payment consideration payable + References No definition available. + Details
Name: | vir_RegulatoryMilestonePaymentConsiderationPayable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty obligation period from date of first commercial sale. + References No definition available. + Details
Name: | vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payment obligation expiration period after first commercial sales. + References No definition available. + Details
Name: | vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone consideration payable. + References No definition available. + Details
Name: | vir_SalesMilestoneConsiderationPayable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sale milestone consideration receivable. + References No definition available. + Details
Name: | vir_SalesMilestoneConsiderationReceivable
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Portion of the carrying value of the equity investment due to a third party that is payable within one year. + References No definition available. + Details
Name: | vir_SharePayableToCollaborator
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Specified development milestones and annual license maintenance fees. + References No definition available. + Details
Name: | vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Specified development milestones payment. + References No definition available. + Details
Name: | vir_SpecifiedDevelopmentMilestonesPayment
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee paid. + References No definition available. + Details
Name: | vir_UpfrontFeePaid
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Written notice period for licensed program, exercise an option. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period for licensed program, failure to make payment + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice for period for licensed program not exercised an option. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period for licensed program other party challenges validity or enforceability of patent license. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period for licensed program, uncured material breach. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period for termination of licensed program. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForTerminationOfLicensedProgram
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period for termination of licensed program based on challenge. + References No definition available. + Details
Name: | vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge
Namespace Prefix: | vir_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_StockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AntibodyProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_VaccineProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementAndStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_BriiBioParentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_LicensedProductByLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstSiRNAProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_CommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_RockefellerUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_FirstFourOtherInfectiousDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AnyOtherInfectiousDiseaseProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_HBVProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndEighteenMedImmuneAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_XencorIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_HBVResearchProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |